Skip to main content
Springer logoLink to Springer
. 2019 Apr 25;37(3):592–593. doi: 10.1007/s10637-019-00773-9

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Kenichi Inoue 1,, Jun Ninomiya 2, Tsuyoshi Saito 3, Katsuhiko Okubo 4, Takashi Nakakuma 5, Hirofumi Yamada 6, Kei Kimizuka 7, Tohru Higuchi 3; for the SBCCSG-36 investigators
PMCID: PMC6828019  PMID: 31025237

Correction to: Investigational New Drugs

10.1007/s10637-019-00755-x

The authors would like to note the replacement of Fig. 2b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.

Fig. 2.

Fig. 2

a Time to treatment failure with eribulin. b Time to treatment failure with trastuzumab and pertuzumab

The original article has been corrected.

Footnotes

The online version of the original article can be found at 10.1007/s10637-019-00755-x

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Investigational New Drugs are provided here courtesy of Springer

RESOURCES